Transcranial LED Therapy for Autism Spectrum Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorder+4 More
Transcranial LED Therapy - Device
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is meant to study whether Transcranial LED Therapy is a safe and tolerable treatment for ASD symptoms and to what extent it may improve symptoms and quality of life.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism Spectrum Disorders
  • Autism, Early Infantile

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Baseline to 8 weeks

Baseline to 8 weeks
Reduction in ASD Symptoms (CGI)
Reduction in ASD Symptoms (SRS)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Transcranial LED Therapy
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Transcranial LED Therapy · No Placebo Group · N/A

Transcranial LED Therapy
Device
Experimental Group · 1 Intervention: Transcranial LED Therapy · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 8 weeks

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,678 Previous Clinical Trials
30,832,163 Total Patients Enrolled
39 Trials studying Autism Spectrum Disorder
2,571 Patients Enrolled for Autism Spectrum Disorder
Tolga A Ceranoglu, MDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital

Eligibility Criteria

Age 18 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Pennsylvania66.7%
New York33.3%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%